About BSIM Therapeutics

About company

BSIM’s mission is to deliver quality drug candidates with high capital efficiency against transthyretin-mediated amyloidosis, including clinical manifestations and related pathologies that represent important and unmet medical needs. Our products are directed to a group of rare, hereditary and fatal pathologies commonly addressed to as Transthyretin Amyloidoses (hATTR). We are developing drug candidates that fit within distinct target-product profiles for the treatment of a broader range of hATTR manifestations, including central nervous system symptoms (e.g. seizures, stroke-like events, progressive dementia) and oculopathy (e.g. vitreous opacities, glaucoma).